Mineralys Therapeutics (MLYS) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Mineralys Therapeutics (MLYS) over the past year, gaining 304.8% versus a loss of 40.7%. Spyre Therapeutics is the larger company by market cap ($8.01 billion vs $2.07 billion), about 3.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MLYS | SYRE |
|---|---|---|
| Share price | $23.37 | $85.69 |
| Market cap | $2.07B | $8.01B |
| 1-day change | +4.42% | +7.25% |
| YTD return | -35.60% | +161.57% |
| 1-year return | -40.67% | +304.77% |
| 5-year return | — | -58.10% |
| EPS (TTM) | $-4.41 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-154.65M | $-155.20M |
| 52-week high | $47.65 | $110.18 |
| 52-week low | $21.46 | $18.12 |
| Distance from 52-week high | -50.95% | -22.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +107.53% | +40.28% |
| Average volume | 1.04M | 1.22M |
| Shares outstanding | 88.41M | 93.45M |
| Employees | 76 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Spyre Therapeutics is about 3.9 times larger than Mineralys Therapeutics by market value ($8.01B vs $2.07B).
- SYRE has outperformed MLYS by 345.4 percentage points over the past year.
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
MLYS vs SYRE FAQ
Which is bigger, Mineralys Therapeutics or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $8.01B compared with $2.07B for Mineralys Therapeutics (MLYS).
Which stock has performed better over the past year, MLYS or SYRE?
SYRE returned +304.77% over the past 12 months, compared with -40.67% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Mineralys Therapeutics and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.